Supernus Pharmaceuticals Total Liabilities 2011-2024 | SUPN
Supernus Pharmaceuticals total liabilities from 2011 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Supernus Pharmaceuticals Annual Total Liabilities
(Millions of US $) |
| 2023 |
$356 |
| 2022 |
$816 |
| 2021 |
$873 |
| 2020 |
$759 |
| 2019 |
$565 |
| 2018 |
$525 |
| 2017 |
$157 |
| 2016 |
$118 |
| 2015 |
$101 |
| 2014 |
$96 |
| 2013 |
$78 |
| 2012 |
$36 |
| 2011 |
$44 |
| 2010 |
$0 |
Supernus Pharmaceuticals Quarterly Total Liabilities
(Millions of US $) |
| 2024-09-30 |
$336 |
| 2024-06-30 |
$358 |
| 2024-03-31 |
$375 |
| 2023-12-31 |
$356 |
| 2023-09-30 |
$373 |
| 2023-06-30 |
$373 |
| 2023-03-31 |
$880 |
| 2022-12-31 |
$816 |
| 2022-09-30 |
$840 |
| 2022-06-30 |
$854 |
| 2022-03-31 |
$811 |
| 2021-12-31 |
$873 |
| 2021-09-30 |
$745 |
| 2021-06-30 |
$787 |
| 2021-03-31 |
$753 |
| 2020-12-31 |
$759 |
| 2020-09-30 |
$801 |
| 2020-06-30 |
$825 |
| 2020-03-31 |
$576 |
| 2019-12-31 |
$565 |
| 2019-09-30 |
$550 |
| 2019-06-30 |
$541 |
| 2019-03-31 |
$545 |
| 2018-12-31 |
$525 |
| 2018-09-30 |
$501 |
| 2018-06-30 |
$462 |
| 2018-03-31 |
$473 |
| 2017-12-31 |
$157 |
| 2017-09-30 |
$134 |
| 2017-06-30 |
$117 |
| 2017-03-31 |
$116 |
| 2016-12-31 |
$118 |
| 2016-09-30 |
$112 |
| 2016-06-30 |
$108 |
| 2016-03-31 |
$97 |
| 2015-12-31 |
$101 |
| 2015-09-30 |
$88 |
| 2015-06-30 |
$82 |
| 2015-03-31 |
$76 |
| 2014-12-31 |
$96 |
| 2014-09-30 |
$90 |
| 2014-06-30 |
$61 |
| 2014-03-31 |
$69 |
| 2013-12-31 |
$78 |
| 2013-09-30 |
$111 |
| 2013-06-30 |
$96 |
| 2013-03-31 |
$38 |
| 2012-12-31 |
$36 |
| 2012-09-30 |
$42 |
| 2012-06-30 |
$42 |
| 2012-03-31 |
$43 |
| 2011-12-31 |
$44 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$0 |
| 2011-03-31 |
$0 |
| 2010-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.962B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
